On Friday, China’s National Medical Products Administration (NMPA) approved Eli Lilly And Co (NYSE:LLY) Tirzepatide for long-term weight management. It is suitable for long-term weight management of adults whose body mass index (BMI) meets the following requirements based on diet control and increased exercise: ≥28 kg/m2 (obese) or ≥24 kg/m2 (overweight) with at least one condition. Tirzepatide is known in the U.S. as Mounjaro for diabetes and Zepbound for weight loss. Related: Chinese Generic Ozempic, Wegovy Versions Could ...